US DoD contracts The Tauri Group for JPM-TMT support services

17 January 2013 (Last Updated January 17th, 2013 03:45)

The Tauri Group has been awarded a contract for providing support services for the US Department of Defense's (DoD) joint project manager transformational medical technologies (JPM-TMT) programme.

The Tauri Group has been awarded a contract to provide support services for the US Department of Defense's (DoD) joint project manager transformational medical technologies (JPM-TMT) programme.

Under the $49m contract, the Tauri Group will serve as the prime contractor and provide a wide range of JPM-TMT advisory and assistance services (A&AS) for the next three years.

Specific A&AS services include support for countermeasure development, biosurveillance, strategic planning and execution, as well as programme communication to the DoD.

“Specific A&AS services include support for countermeasure development, biosurveillance, strategic planning and execution.”

Tauri Group TMT programme manager John David said the company has been handed the responsibility of safeguarding soldiers from continuing threat of biological weapons.

"We have been a part of this effort for the last four years and we are looking forward to be part of the continued success of the TMT programme," he said.

JPM-TMT is a component of the DoD's Joint Program Executive Office for Chemical and Biological Defense (JPEO-CBD), and aims to safeguard troops from a wide range of emerging infectious diseases, genetically altered and unknown biological threats during deployments or at home.

Collaborating with biotech and pharmaceutical companies, government agencies and academica, the programme employs innovative technologies and non-traditional approaches to augment the DoD's national biodefence strategy and the integrated national biodefence medical countermeasures portfolio.

Working in compliance with the US Food and Drug Administration's (FDA) drug approval process, the programme seeks advanced development and acquisition of adaptable, broad-spectrum medical countermeasures (MCM) to treat personnel infected with new and evolving bio-threats.